English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

No observational studies have evaluated the "real-world" effectiveness of dual bronchodilation comprising a long-acting β 2 -agonist plus a long-acting muscarinic antagonist vs that of triple therapy (long-acting β 2 -agonist plus long-acting muscarinic antagonist plus inhaled corticosteroid) in COPD.

Dual bronchodilation vs triple therapy in the &ldquo;real-life&rdquo; COPD DACCORD study

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study